Ver­tex wa­gers $70M on Kymera and its new fas­ci­na­tion with pro­tein degra­da­tion

One of Ver­tex’s key promis­es to in­vestors and pa­tients has been that it will de­ploy its suc­cess in cys­tic fi­bro­sis — which fi­nal­ly turned the 30-year-old biotech in­to a prof­itable busi­ness three years ago — to fund more R&D projects with in­no­v­a­tive tech­nolo­gies. It has pro­pelled them to dive in­to gene edit­ing, team up with CRISPR Ther­a­peu­tics to test what could be a pi­o­neer­ing treat­ment for sick­le cell dis­ease.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER